Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Vista sencilla de ítem
dc.creatorWilliamson, Brandi N
dc.creatorFeldmann, Friederike
dc.creatorSchwarz, Benjamin
dc.creatorMeade-White, Kimberly
dc.creatorPorter, Danielle P
dc.creatorSchulz, Jonathan
dc.creatorVan Doremalen, Neeltje
dc.creatorLeighton, Ian
dc.creatorYinda, Claude Kwe
dc.creatorPérez-Pérez, Lizzette
dc.creatorOkumura, Atsushi
dc.creatorLovaglio, Jamie
dc.creatorHanley, Patrick W
dc.creatorSaturday, Greg
dc.creatorBosio, Catharine M
dc.creatorAnzick, Sarah
dc.creatorBarbian, Kent
dc.creatorCihlar, Tomas
dc.creatorMartens, Craig
dc.creatorScott, Dana P
dc.creatorMunster, Vincent J
dc.creatorDe Wit, Emmie
dc.date.accessioned2020-07-17T23:18:04Z
dc.date.available2020-07-17T23:18:04Z
dc.date.created2020-06-09
dc.description.abstractenglishEffective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.7,8 Here, we investigated the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection9. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs and reduced virus titers in bronchoalveolar lavages 12hrs after the first treatment administration. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment. At necropsy, lung viral loads of remdesivir-treated animals were lower and there was a reduction in damage to the lungs. Thus, therapeutic remdesivir treatment initiated early during infection had a clinical benefit in SARS-CoV-2-infected rhesus macaques. Although the rhesus macaque model does not represent the severe disease observed in a proportion of COVID-19 patients, our data support early remdesivir treatment initiation in COVID-19 patients to prevent progression to pneumonia.spa
dc.format.extent17 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41586-020-2423-5spa
dc.identifier.issn1476-4687spa
dc.identifier.otherhttps://www.nature.com/articles/s41586-020-2423-5#article-infospa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10820
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectRemdesivirspa
dc.subject.keywordRemdesivirspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleClinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41586-020-2423-5_reference.pdf
Tamaño:
8.25 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS